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We  have  previously proposed  a  model  for  the  molecular assembly  of  the  C5-91 
complex  on  the  surface  of  cells  under attack  by  complement  (1).  This  model  was 
based on experiments with radiolabeled isolated proteins that allowed quantification 
of  the  molar  ratios  of  specifically  bound  complement  molecules.  It  envisioned a 
decamolecular  complex,  in which  all  five  components  were  tightly  bound  to  each 
other, having a  total tool wt of 995,000 daltons. Since these studies were confined to 
the  cell-bound complex,  hydrodynamic measurements could  not be performed. 
We now want to report the successful attempt to produce a  stable C5-9 com- 
plex  in cell-free solution. This free  complex was  found  to  be  a  by-product  of 
immune  cytolysis.  It  further  could  be  induced  in  the  absence  of  cells  by  a 
variety  of  complement  activators.  Its  composition  was  found  to  consist,  as 
predicted,  of C5,  C6,  C7,  C8,  and C9.  The  molecular weight  closely approxi- 
mates  the  anticipated  value.  The  data  to  be presented  substantiate  the  pre- 
viously advanced concept3 
Materials and Methods 
Human Complement Components.--C3 (2), C5 (2), C6 (3), and C73 were isolated in highly 
purified form according to previously published methods. Highly purified C8 and C9 were 
prepared by modifications of the previously published methods (4, 5), which will be presented 
in detail elsewhere. 4 All five proteins were  judged free  of  demonstrable contamination by 
chromatographic,  electrophoretic,  and  immunochemical criteria.  They were  trace  labeled 
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with either 12~I or  1311 by the chloramine-T method of McConahey and Dixon  (6).  Mter 
labeling, each component was dialyzed for 48 h  against 4  )< 10 liters of 0.15 M  NaC1 con- 
taining 50 mM  chloramphenieol (donated by Parke,  Davis and Company,  Detroit,  Mich.) 
and 25 #M kanamycin sulfate (Bristol Laboratories, Syracuse, N. Y.). The dialyzed prepa- 
rations were centrifuged for 2  h  at 98,000 g to remove aggregates.  Bovine serum albumin 
(BSA)  (Pentex Biochemical, Kankakee, Ill.) was added to a  final concentration of 1 mg/ml 
and the preparations were stored at 0°C.  The 125I- and  131I-containing samples were ana- 
lyzed with a  Nuclear-Chicago dual-channel, automatic, well-type gamma counter (Nuclear- 
Chicago Corp., Des Plaines, Ill.). 
Preparation of Sheep Erythrocyte-Antibody-Complement Complexes.--EAC1,  4,  °xy2  (7), 
EAC1, 4,  °xy2, 3  (1),  EAC1-7, and EAC1-8  (1) were prepared according to  previously pub- 
lished methods. 
Complement Activators.--HSFa  (C3b)  was  prepared  as  described  (8).  Antigen-antibody 
(Ag-Ab) complexes were made at fivefold antibody excess by mixing 20/~g of BSA and 10 ml 
of rabbit anti-BSA (1.6  mg of Ab N2/ml). The mixture was incubated at 37°C  for 2 h  and 
then at 4°C for 16 h. The antigen-antibody complexes were collected by centrifugation and 
washed four times with 25 ml of Veronal-buffered saline (VB). The final precipitate was re- 
suspended to 2 ml of VB and the protein concentration determined by the Lowry method (9) 
using Cohn fraction II as a standard. 2 g of inulin (Pfanstiehl Laboratories, Inc., Waukegan, 
Ill.) was washed four times with 50 ml of VB and resuspended to 10 ml (200 mg/ml). 2 g of 
zymosan (Nutritional Biochemical Corp., Cleveland, Ohio) was refluxed in 0.15 M  NaCl for 
3  h, washed four  times with 50 ml of VB, and resuspended to 20 ml  (100  mg/ml).  Cobra 
venom  factor  (CVF)  was  prepared  as  described  (10).  When  EA,  antigen-antibody com- 
plexes,  inulin,  or zymosan were used  as activators,  the indicated amounts were placed  in 
10 X  75-mm Falcon plastic tubes (Falcon Plastics, Division of BioQuest, Oxnard, Calif.) and 
centrifuged  in  a  tabletop  Sorvall  Model  GLC-1  centrifuge  (Ivan  Sorvall,  Inc.,  Norwalk, 
Conn.) for 10 rain at 1200 g. The supernatant fluid was removed and freshly drawn human 
serum  (HS), containing the indicated radiolabeled proteins, was added. After incubation at 
37°C  for 2 h, the reaction mixture was centrifuged and the supernatant subjected to sucrose 
density gradient analysis, column chromatography, or preparative electrophoresis. 
Purification of the C5-9 Complex.--25 ml of freshly drawn HS, containing 200 #g of [125I]C8, 
was incubated with 400 mg of zymosan at 37°C for 90 min with frequent mixing. The zymo- 
san particles were removed by centrifugation at  1200 g and the supernatant was subjected 
to ascending chromatography on a  Bio-Gel A-15M column  (5  X  90 cm)  (Bio-Rad Labora- 
tories, Richmond, Calif.). The column had been equilibrated and was eluted with VB con- 
taining 1 mg of sodium azide/ml. The flow rate was 15 ml/h and 5-ml fractions were collected. 
Fractions containing the C5-9 complex, as measured by the incorporated [125I]C8 (see Fig. 6), 
were pooled and concentrated by ultrafiltration to a  volume of 10 ml. This pool was rechro- 
matographed on the same column under the same conditions. The ascending portion of the 
C5-9 peak was pooled and concentrated to 3 m]. The preparation was centrifuged at 1500 g 
for 30 min and passed through a  Millipore filter (0.45/zm pore size)  (Millipore Corp., Bed- 
ford,  Mass.).  Chloramphenicol and kanamycin were  added  to  a  final concentration of  50 
mM and 25 #M, respectively. It was stored at 0°C until used. 
Elution of C5-9 Complex  from Complement-Lysed EA.--2 ml of  iodine-treated serum (11), 
containing either 10 #g of [125I]C9 or 5 #g of [125I]C8, was added  to a pellet of  10  TM EA and 
incubated at 37°C  for 3 h with constant mixing. The reaction mixture was then centrifuged 
in a  fixed  angle Beckman 40 rotor (Beckman Instruments, Inc., Palo Alto, Calif.) for 2 h  at 
35,000 rpm. The supernatant was removed and the membrane-containing pellet washed with 
4  X  2 ml of VB. The pellet from EA lysed with [12~I]C8 containing HS was resuspended in 
400 #1 of VB and divided into two aliquots that were stored for 120 h at --70°C or 4°C.  The 
pellet from EA lysed with [125I]C9 containing HS was resuspended in 200 #1 of VB containing 
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ticulate material was removed by centrifugation at 5000 g for 1 h, and the supernatant sub- 
jected to sucrose density gradient analysis. 
Sucrose Density Gradient Ultracentrifugation.--lO-40% linear  sucrose  gradients,  made 
with VB, pH 7.5, ionic strength 0.15, were formed in 5-ml cellulose nitrate tubes. The sample 
size was 100-200 #l and centrifugation was performed in a  Beckman SW 50 or SW 50.1 rotor 
(Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) for 16 h  at 35,000 rpm and 4°C. 
Fractions were collected in a  dropwise manner (10 drops each)  after puncturing the bottom 
of the tubes. 
Determination of the Diffusion Coefficient of the C5-9 Complex.--750 ml of Bio-Gel A-15M 
(Bio-Rad Laboratories) was equilibrated with VB, containing 1 mg of sodium azide/ml. The 
gel was deaerated  under vacuum for  2  h  with frequent mixing and packed  in a  2.0 X  100 
cm  column  (Pharmacia  Fine  Chemicals,  Uppsala,  Sweden).  2~  ml  of  freshly drawn  HS, 
containing either  2  #g of  [12~IJC9  or  1 #g of  [12~I]C8,  was incubated with 40 mg of inulin 
for 2 h  at 37°C with frequent stirring. The inulin was removed by centrifugation and various 
markers were added to the supernatant before it was analyzed by ascending molecular sieve 
chromatography. VB was used as eluting buffer and the flow rate was 8 ml/h. 2-ml fractions 
were collected and assayed for  125I and  131I radioactivity, protein  distribution,  and absorb- 
ance at 412 nm to quantitate the hemoglobin marker. 
Pevikon Block Electrophoresis.--Small particles were removed from  the Pevikon  (Mercer 
Consolidated Corp., Yonkers, N. Y.) by stirring and decanting the supernatant after the large 
particles had been allowed to settle. This was repeated five times in water. The Pevikon was 
equilibrated with barbital buffer, pH 8.6, ionic strength 0.05, and poured into a  1  X  15  X  50 
cm block. The sample consisted of 5 ml of HS diluted 1 : 1 with VB and 150 #1 containing 40 
/zg of purified  C5-9  complex having incorporated  [I25I]C8.  It was applied  7.5 cm from  the 
cathodal end of the block. Electrophoresis was carried out for 36 b  at 3 V/cm and 4°C.  1.25- 
cm segments were cut and eluted twice with 5 ml of saline. All eluates were adjusted to a final 
volume of 15  ml and analyzed for protein,  125I content,  and C8 and C9 hemolytic activity. 
The electrophoretic  mobility of  the  C5-9 complex was estimated using a  straight line plot 
of the relative distance traveled  by reference proteins on  the  same Pevlkon block vs.  their 
electrophoretic mobility in free solution at an identical pH. The reference proteins and their 
respective  mobilities are:  IgG,  --1.2  X  10  -5  cm  2 V -1  s-l;  transferrin,  --3.10 )K  10  -6 cm  2 
V  -1  s-l;  albumin,  --5.92  X  10  -5  cm 2 V -1  s  -1  (12). 
Measurement of Competition between C5-9 Complex and I'2AC1-8 for  Cg.--EAC1-8  were 
made by incubating  10 ml of  EAC1-7  (1.5  X  10S/ml) with 2 #g of  purified  C8 for 30  min 
at 37°C.  The cells were washed four times with  10 ml gelatin  containing Veronal-buffered 
saline (GVB)  and  standardized  to  1.5  >(  10S/ml.  Increasing amounts of purified  C5-9 com- 
plex were incubated with 3  X  107 EAC1-8 and 3 #g of C9 in a  total volume of 500 #1.  After 
60 rain incubation at 37°C  the reaction was terminated  by the addition of 1 ml of ice cold 
GVB  and centrifuged for  10 rain at 800 g.  The released oxyhenmglobin was quantitated at 
412 nm and the percent of inhibition of EAC1-8 lysis by C5-9 complex was determined. 
Binding of [12~I]C9 to Preformed C5-9 Complex.--400 #1  of freshly drawn HS containing 
5/zg of [1~1I]C8 was incubated with 10 mg of zymosan at 37°C for 90 min. The zymosan was 
removed by centrifugation and 200 #1 of the supernatant was stored at 0°C while the remain- 
ing 200 #l was reincubated with 2 #g of [125I]C9  at 37°C for 90 min. Both supernatant sam- 
ples were subjected to sucrose density gradient analysis. 
The Reaction Kinetics of Removal of PTuid Phase C9 by C5-9 Complex.--1 #g of  purified 
C9 was mixed with 25,  125, or 250/~g of purified C5-9 complex in  1 ml of  GVB at 0°C. The 
reaction mixtures were transferred to 37°C and at various times 50-#1 samples were taken and 
diluted  in  5  ml of  ice-cold  GVB.  All  samples were  then assayed for residual  C9  hemolytic 
activity.  200/~1 were  added  to  EAC1-8  (3  X  107)  and incubated  in  a  total  volume of 500 
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RESULTS 
Formation of the Soluble C5-P Complex by Activation  of the Classic Comple- 
ment  Pathway.--Verification  of  the  C5-9  complex,  previously  postulated  to 
assemble  on  a  target  membrane  attacked  by  complement,  depended  on  the 
possibility  of  its  occurrence  in  free  solution.  As  an  initial  approach  we  at- 
tempted  elution  of  the  complex  from  EA  that  had  been lysed with  human 
serum containing either radiolabeled C8 or C9. After treatment of the washed 
EA-membranes with  SDS or by prolonged storage at 4°C or --70°C,  the elu- 
ates were examined by sucrose density ultracentrifugation.  As seen in Fig.  1, 
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FIG.  1. Ultracentrffugal demonstration of rapidly sedimenting C8 and C9 ill eluates from 
EA lysed by complement (fractions 4-12). Lysis was effected by HS containing [z25I]C8  or 
[t2~I]Cg. The washed membranes were incubated  with 1% SDS at 37°C for 16 h or stored 
at either  --70°C or 4°C for 120 h. The particulate  material was removed by centrifugation 
and the supernatants  were subjected to ultracentrifugation  in a 1040% linear sucrose den- 
sity gradient at 35,000 rpm for 16 h. Direction of sedimentation was to the left. 
each eluate contained fast and slowly sedimenting  radiolabeled  material.  The 
fast  component was indicative  of elution of a high molecular weight complex 
containing C8 and C9. 
Next,  we examined  the  possibility  of formation  of a  C5-9  complex in  the 
fluid  phase.  Samples  of  human  serum  containing  radiolabeled  complement 
proteins were treated  with EA or antigen-antibody precipitates.  Examination 
of  treated  and  untreated  serum  by  ultracentrifugation  showed  that  both 
activators  initiated  the  formation  of heavy,  radioactive  material.  As demon- 
strated in Fig. 2, the heavy material contained C5, C6, C8, C9, and, not shown 
in this illustration,  also C7. No such heavy material formed when fresh serum 442  MEMBRANE  ATTACK  MECHANISM  OF  COMPLEMENT.  II 
was  incubated  without  complement  activators.  Consistently  more  heavy 
complex was formed when antigen-antibody precipitates were used than when 
EA  served  as  activator.  In  the  case  of  EA-induced activation,  a  significant 
proportion of the C5-9 complex formed was found to be bound to membrane 
receptors instead of accumulating in the fluid phase. 
Formation of the Soluble C5-9 Complex by Activation  of the Alternate Comple- 
ment  Pathway.--Various  substances  were  employed  as  activators  of  the  al- 
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Fro. 2. The formation of a stable and solubie C5-9 complex as a by-product of complement 
activation by the classical pathway and its demonstration by zone ultracentrifugation. 1.5 X 
l09 EA or 2 mg of BSA-anti-BSA immune complexes were incubated with 200 #1 of freshly 
drawn HS containing  the indicated radiolabeled complement  proteins for 2 h at 37°C. The 
EA membranes  or  antigen-antibody (Ag-Ab) aggregates were  removed  by centrifugation 
and  the  supernatants  subjected to  sucrose  density gradient analysis.  The  control,  which 
consisted of 200 #1 of HS containing [125I]C9, received no complement activator. 
ternate  pathway.  Fig.  3  shows  the  results  obtained  with  particulate  inulin, 
a  polyfructose.  C5,  C7,  C8, C9,  and,  not  shown  in  this  illustration,  C6  were 
incorporated  into  the  rapidly sedimenting  radiolabeled  component.  In  con- 
trast,  radiolabeled C3  was  not  detected in  the  C5-9  complex  (Fig.  3,  bottom 
panel).  In  other  control  experiments,  [131I]IgG  and  [131I]albumin  were  also 
excluded as constituents of the complex. 
Table I  lists the substances that have been employed in this study as com- 
plement  activators.  Under  the  conditions  used,  it  is  difficult to  judge their 
relative capacity to induce  C5-9  complex formation.  Nevertheless,  a  reason- WILLIAM  P.  KOLB  AND  HANS  J.  MULLER-EBERHARD  443 
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FIG. 3.  The formation of a  stable and soluble C5-9 complex as a  by-product of comple- 
ment activation by the alternate pathway. 4 mg of inulin was incubated with 200 #1 of freshly 
drawn HS containing the indicated radiolabeled complement proteins as outlined in the legend 
to Fig. 2. 
TABLE  I 
Formation of the C5-9  Complex and Consumption of Complement Activities in tluman Serum 
on Treatment with Various Activators 
Complement activator  Ability to form fluid 
phase C5-9  complex 
Consumption of hemolytic activity 
C5  C8  C9 
% 
None  0  0  0  0 
EA  q- *  60  73  100 
HSFa (C3b)  +  10  17  27 
Ag-Ab complex  +  +  +  50  42  82 
Inulin  q- q- q- q-  80  47  100 
Zymosan  q- q- q- +  100  100  100 
CVF  q- +q-q-  100  38  60 
Conditions: 200 #1 of serum were treated for 2 h  at 37°C  with 1.5 
HSFa,  2 mg of Ag-Ab, 4  mg of inulin, 2 mg of zymosan, or 25/zg of 
* Estimated relative size of the 22.4S component. 
X  109 EA,  100 #g of 
CVF. 
able  correlation  is  apparent  between  efficiency  of  formation  of  the  complex 
and consumption of C5,  C8,  and C9. 
Physicochemical  Properties  of  the  Soluble  C5-9  Complex.--Physicochemical 
measurements  were  performed  on  the complex  generated in serum by  activa- 444  MEMBRANE  ATTACK  MECHANISM  OF  COMPLEMENT.  II 
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]~'IO. 4. Sucrose density gradient analysis of the C5-9 complex. Inulin-initiated  C5-9 com- 
plex formed in HS containing  [125I]C9 was analyzed,  as outlined  in  the  legend to Fig.  1, 
with the following reference proteins:  [131I]thyroglobulin (Thy), [131I]IgG,  and hemoglobin 
(/SD). 
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FIO. 5. Determination  of the sedimentation coefficient of the C5 9 complex. The data were 
derived from two separate experiments as outlined in Fig. 4. 
tion with  inulin.  The complex contained  either  [125I]C8 or [t2~I]C9. The  sedi- 
mentation  coefficient  was  determined  by  sucrose  density  gradient  ultraeen- 
trifugation  (Fig.  4)  using  hemoglobin  (4.5S),  IgG  (7S),  and  thyroglobulin 
(19S)  as reference substances.  It was found to be 22.5S  (Fig. 5). The diffusion 
coefficient  was  estimated  by  gel  filtration  using  Bio-Gel  A-15M  (Bio-Rad 
Laboratories)  (Fig.  6).  Keyhole  limpet  hemocyanin  (KLH),  thyroglobulin, 
IgG,  serum  albumin,  and  hemoglobin  served  as  reference  substances  with 
known diffusion  coefficients.  By plotting  elution  volume vs.  the  reciprocal  of 
D  according to Andrews  (13),  D  of the complex was found to be 1.98  X  l0  -7 
cm2/s  (Fig.  7).  Assuming a  ,7  of 0.73,  these  data  allowed  calculation  of the 
molecular weight and frictional ratio (Table II). 
The  electrophoretic  mobility  of  the  C5-9  complex  was  determined  at  pH 
8.6 on Pevikon blocks and was found to be --4.7  X  10  -s cm  2 V -t s  -t  (Fig. 8). 
Stability  of the Soluble C5-9 Complex.--The  complex retained  its  sedimen- 
tation  and  elution  characteristics  on  repeated  ultracentrifugation  and  gel WILLIAM  P.  KOLB  AND  HANS  J.  M13LLER-EBERHARD  445 
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FIG. 6.  Molecular sieve chromatography of Lhe C5-9 complex.  [125I]C9 containing C5-9 
was subjected to chromatography on Bio-Gel A-15iVf (2 X  85 cm column) using [131I]KLH, 
[131I]thyroglobulin,  [131I]IgG, HSA, and hemoglobin as reference proteins. The column was 
equilibrated and eluted with VB containing 1 mg of sodium azide/ml. 
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FIG.  7.  Determination of the diffusion  coefficient  of the C5-9 complex.  The data for the 
Andrew plot are derived from experiments illustrated in Fig. 6. The diffusion  coefficients  of 
the reference proteins are: thyroglobulin, 2.5  X  10  -7 cm2/s; IgG, 3.8 X  10  -7 cm2/s; albu- 
min, 6.1  X  10  -7 cm2/s; hemoglobin, 6.8  X  10  -7 cm2/s. 
filtration,  respectively.  Its  size was  unchanged  after  storage  for  6  wk  at  4°C 
and  pH  7.4.  No  evidence was  obtained  for spontaneous  dissociation  into  sub- 
components.  Preliminary  results  indicate,  however,  that  dissociation  can  be 
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TABLE  II 
Physicochemical Param,ters of C5-9 Complex 
Sedimentation  coefficient 
Diffusion coefficient 
Mol wt 
Frictional ratio 
Electrophoretic mobility (pH 8.6) 
22.5S 
1.98  X  10  -7 cm2/s 
1.04  X  l0 G 
1.48 
-4.7 X  10  -5 cm  2 V  -1 s  -1 
E 
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FIG.  8.  Electrophoretic  behavior  of C5-9  complex. [125I]C8-radiolabeled C5-9 complex 
was introduced  into HS and  analyzed  by Pevikon block electrophoresis at pH 8.6. Arrow 
indicates origin. 
Does  the  Soluble  CS-P  Complex  Have  Hemolytic  Activity?--C5-9  complex 
from  sucrose  density  gradients  (Figs.  2  and  3)  and  gel  filtration  fractions 
(Fig.  6)  was tested  for hemolytic activity using E,  EA,  and  various interme- 
diate  complexes  of  EA  and  complement  proteins.  No  hemolytic  effect  was 
detected  even  when  several  thousand  C5-9  complexes  were  offered per  cell. 
In addition,  the complex was found not to bind to any of the EA-complement 
intermediates  tested. 
Ability of the Soluble C5-9 Complex to Bind Additional  cg.--Fig.  9  demon- 
strates that  the  C5-9 complex is able  to inhibit  lysis of EAC1-8 by C9.  This 
finding  suggested  that  the  complex  was  not  fully  saturated  with  respect  to 
its  C9  binding  sites  and  thus  capable  of adsorbing  additional  C9  molecules 
from  the  fluid  phase.  Binding  of  C9 was  directly  demonstrated  by  treating 
[1~1I]C8 containing  C5-9  complex  with  [1~5I]C9. The  treated  and  untreated 
samples  were  then  analyzed  by zone ultracentrifugation.  As seen  in  Fig.  10, 
treatment  with  C9 resulted  in binding  of a  small  but  definite  amount  of C9 
to  the  complex.  Binding  was  rapid  (Fig.  11)  and  required  a  molar excess  of 
complex over free C9. These data indicate  that only a  small  fraction  (2-5 %) 
of complexes  are  capable  of adsorbing a  small  amount  of additional  C9. WILLIAM  P.  KOLB  AND  HANS  J.  M'ULLER-EBERHARD  447 
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FIG. 9.  Competitive inhibition by C5-9 complex of lysis of EAC1-8 by C9. EAC1-8, C9 
(830 molecules per cell) and increasing amounts of purified C5-9 complex were incubated at 
37°C for 60 min. The arrow indicates the point at which the number of C5-9 complexes offered 
equals the number of membrane-bound C5-8 sites. 
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FIG.  10. Binding of additional [12~I]C9 to the soluble C5-9 complex.  [lSlI]C8 containing 
HS was activated with zymosan at 37°C for 90 min. An aliquot of the supernatant was incu- 
bated with [125I]C9 at 37°C  for an additional 90 min. Both the original and [125I]C9-treated 
supernatants were subjected to sucrose density gradient analysis as seen in the top and bottom 
panels, respectively. 
DISCUSSION 
The molecular model advanced previously for the membrane attack mecha- 
nism of complement was deduced from data concerning the molar ratios  and 
topological relationship of cell-bound complement proteins (1). The objective 
of  the  present  study  was  to  test  the  proposed  model  experimentally.  The 
primary prerequisite for such exploration  was  the possibility of forming the 
stable complex in cell-free solution. 
The results presented show that a stable, soluble multimolecular complex is 
generated in whole human serum as a by-product of activation of the classic 448  MEMBRANE  ATTACK  MECHANISM  OF  COMPLEMENT.  II 
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FIG. 11. Kinetic analysis of C9 consumption by soluble C5-9 complex. 1 #g of C9 was in- 
cubated with 0. 25, 125, or 250 #g of highly purified C5-9 complex in 1 ml of GVB at 37°C. 
Aliquots were withdrawn at the indicated time, diluted 100-fold in 0°C GVB, and assayed 
for remaining C9 hemolytic  activity. The molar ratios of C9 to C5-9 complex were calculated 
assuming the tool wt of C9 to be 79,000 and that of the C5-9 complex 1.04 N 106. 
and  alternate  pathways  of  complement.  This  complex was  shown  to  incor- 
porate C5  (according to earlier evidence as C5b [14, 15]), C6,  C7,  C8,  and C9. 
It does not contain  C3 or noncomplement proteins  such as  albumin  or IgG. 
Although its precise composition in quantitative terms is not yet known,  the 
measured mol wt of the soluble  complex, 1.04 X  106, is in excellent agreement 
with  the  calculated mol wt of the  cell-bound complex, 0.995  X  l0  t  (1).  The 
composition of the cell-bound complex was delineated as containing one mole- 
cule  each  of C5,  C6,  C7,  and  C8 and,  at saturation  of all  C9  binding sites, 
six molecules of C9. The similarity of the molecular weights suggests a similar, 
if not identical,  subcomponent composition for the  soluble  C5-9 complex. 
The soluble complex displayed stability in  aqueous solution over extended 
periods  of  time,  but  this  stability  was  not  due  to  covalent  bonding  of  the 
units: complete dissociation was observed by 0.1% SDS. Its net surface charge 
was relatively negative considering the charge of the individual subcomponents, 
all  but  C9  being  fl-~,l-globulins.  Nevertheless,  the  complex  behaved  as  an 
o~-globulin, having  the  same  electrophoretic  mobility  at  pH  8.6  as  C9.  This 
observation suggests that a major portion of the surface of the  tetramolecular 
C5-8 complex is covered by C9 molecules (1). 
Some observations made by others  are pertinent  to this  study.  Thompson 
and Lachmann (16,  17)  reported  the occurrence of a  stable bimolecular  com- 
plex of C5  and  C6,  C5,  6,  which formed after activation of C5  by zymosan. 
The "(25, 6, on interaction with C7,  was shown to be able to bind to  erythro- 
cytes. Although these conclusions were drawn from work with serum reagents, 
the  3  - were confirmed and extended by work with highly purified complement 
proteins  (18,  19).  The occurrence of a  C5,  6,  7 complex in free solution was 
postulated  by Lachmann and  Thompson  (17)  and  by Koethe  et  al.  (20)  on 
the basis of C8 consumption and incorporation of radiolabeled  C5  into high- WILLIAM P.  KOLB AND HANS J.  MOLLER-EBERHARD  449 
molecular weight material.  Similarly, the occurrence of a  C5-8  complex was 
inferred from the finding of C9 consumption by material excluded on Sephadex 
G-200 (Pharmacia) (20). Thus, earlier indirect evidence suggested the existence 
of free C5, 6-, C5, 6, 7-, and C5, 6, 7, 8-complexes. 
A  sideline of  our work,  suggested  by observations  of  Koethe  et  al.  (20), 
was the demonstration that a proportion of the C5-9 complexes are capable of 
physically binding additional C9. Obviously some C9 binding sites on the C5-9 
complex were  unsaturated,  explaining  its  inhibitory  effect on  EAC1-8  lysis 
by C9. 
The following dynamic molecular concept of the membrane attack mecha- 
nism of complement is proposed (Fig.  12).  In their native form the five pro- 
teins of the attack system exhibit affinity for each other (19,  21). They enter 
into reversible interactions such  that C5  associates with C6 and C7, C8 with 
C5, 6, 7, and C9 with C8 and thus with C5, 6, 7, 8 (22). Formation of the stable 
C5-9 complex proceeds by self-assembly after enzymatic activation of C5  by 
the  C5  convertases of  the  classic  or  alternate  pathways.  On  activation,  C5 
is  cleaved  and  a  low  molecular weight  fragment  (C5a)  is  dissociated.  As  a 
result, the large fragment, C5b, probably undergoes a  conformational change 
allowing  adsorptive  binding  of  C6  and  C7.  The  trilnolecular  complex con- 
stitutes  the  critical  molecular arrangement  for binding  by  adsorption  of  C8 
and  C9.  It is  emphasized that  the only demonstrable  enzymatic reaction in 
the  entire  assembling  process  is  that  involving  C5.  All  subsequent  events 
appear  to  be  governed by  nonenzymatic,  physicochemical  reactions  with  a 
high degree of stereochemical specificity. 
Through its C5, 6, 7 portion the complex is enabled to associate itself firmly 
with receptors of the outer membrane of  cells.  As  a  consequence, the mem- 
FIG. 12. Schematic  representation of formation of a stable C5b-9 complex. On activation 
of C5, association of components C5b to C9 into a firm complex ensues. This complex  has 
the transient capacity to bind to the surface of a cell and to cause cell lysis. On loss of its 
binding site the stable arrangement remains in free solution without cytolytic activity. 450  MEMBRANE  ATTACK MECHANISM  OF  COMPLEMENT.  II 
brane sustains  damage and  the cell  undergoes  osmotic lysis.  The capacity of 
the  complex  to  bind  to  membrane  receptors  is  highly  transient  and  unless 
binding  is achieved within  less  than  0.1  s  (18),  the  activated binding  site is 
irreversibly lost.  The decay product,  C(Sb,  6,  7,  8,  9)i,  remains  as  a  stable 
complex in cytolytically inactive form in the fluid phase. 
Thus,  the  nascent  C5-9  complex may have  two  fates with  respect  to  en- 
vironment and  function.  The cell-bound  complex partially enters  the hydro- 
phobic milieu of the membrane interior causing a rearrangement of its  micro- 
environment  and  thereby  functional  membrane  impairment.  The  unbound 
complex  remaining  in  aqueous  solution  possesses  hydrophilic  properties  and 
lacks membranolytic functions. Although both forms appear to be decamolec- 
ular,  they  most  probably  differ  in  quaternary  structure  imposed  by  their 
disparate environments. Work is underway to determine whether  the  soluble 
C5-9 complex has any noncytolytic biologic activity. 
SUMMARY 
The membrane attack mechanism of complement, C5  to C9, has previously 
been postulated to associate on the target cell surface to a stable decamolecular 
complex with a calculated mol wt of 995,000. 
A soluble and stable complex consisting of C5, C6, C7, C8, and C9 has now 
been  demonstrated  to  arise  as  a  consequence  of  complement  activation  by 
the classical or alternate pathway. It has a  sedimentation coefficient of 22.5S 
and  a  mol wt of 1 million daltons,  and it migrates on electrophoresis  at pH 
8.6 as an a-globulin. 
The stable and soluble C5b-9 complex cannot bind to erythrocytes and has 
no  demonstrable  cytolytic  activity.  However,  due  to  partially  unsaturated 
binding  sites for C9,  it  can  bind  additional  C9  and  thus  /unction  as  an in- 
hibitor  of lysis of EAC1-8  by C9. 
These results support the concept according to which the membrane-bound 
attack system of complement represents a  stable,  decamolecular assembly of 
C5b-9.  Unlike its analogue in free solution,  the membrane-bound complex is 
cytolytically active. 
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